See the DrugPatentWatch profile for Tisotumab
What is tisotumab vedotin, and what is it used for?
Tisotumab vedotin is an antibody-drug conjugate (ADC). It pairs an antibody that targets a protein on tumor cells with a chemotherapy payload, delivering the drug into cells that express the target.
It is used to treat certain cancers in which its target is present and in settings defined by regulators and clinical evidence (for example, some patients with recurrent or metastatic cervical cancer). [1]
How does tisotumab vedotin work?
Tisotumab vedotin is designed to bind to a specific surface marker on cancer cells, then enter the cell. After internalization, the drug releases its cytotoxic payload to kill the cell. [1]
What patients commonly ask: how is it given?
Tisotumab vedotin is given by intravenous infusion as prescribed in the relevant treatment regimen. The exact dosing schedule depends on the approved indication and local prescribing information. [1]
What side effects are associated with tisotumab vedotin?
Commonly reported adverse effects for tisotumab vedotin include treatment-related eye problems (such as dryness, redness, irritation, or keratitis) and other chemotherapy-type effects like fatigue and nausea, depending on the study and patient population. [1]
Because of the known eye risk, clinical care typically includes eye monitoring and preventive/supportive eye measures as recommended in the prescribing information or oncology care pathway. [1]
Why do clinicians monitor the eyes with this drug?
The drug has a specific safety signal affecting the eye. That risk is why clinicians recommend regular eye assessments and interventions to reduce severity and catch problems early. [1]
Who makes it, and what approvals matter for where you live?
Tisotumab vedotin is the branded ADC product “Tivdak.” Availability and the exact approved patient populations, line of therapy, and companion requirements depend on the country and regulator. [1]
Where can I find the official label details (dose, schedules, warnings)?
The most reliable source is the regulatory prescribing information for your region (dose, infusion details, dose modifications, contraindications, and detailed warnings). The Tivdak prescribing information is where eye-management recommendations and other safety requirements are spelled out. [1]
Sources:
1. https://www.tivdak.com/